Physician profile
Marshall Ching
NPI 1215036835
$17,844,329.33
in general payments reported to CMS, 2019-2025
13 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.3M · 2020: $15M · 2021: $1.2M · 2024: $611K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $656K · Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $655,656.26 |
| Food and Beverage | $623.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $14,706,404.40 | 2020 | |
| Medtronic, INC. | $1,810,157.64 | 2021-2025 | Inpen Smart Insulin Delivery System |
| Medtronic Vascular, INC. | $879,023.77 | 2019 | |
| Medtronic USA, INC. | $447,206.25 | 2019 | |
| Zimmer Biomet Holdings, INC. | $1,236.31 | 2019-2025 | Rosa, Persona, Juggerknotless Soft Anchor |
| Pacira Therapeutics, INC. | $95.36 | 2020-2021 | |
| Sonex Health, INC. | $56.57 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $54.05 | 2024 | Exparel, Zilretta, Iovera |
| Ethicon US, LLC | $33.52 | 2024 | Stratafix |
| Heron Therapeutics, INC. | $22.70 | 2024 | Zynrelef |
| Acell, INC. | $21.08 | 2019 | |
| Abbott Laboratories | $17.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,504,882.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Ching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.